


MEDICINAL PRODUCTS 2023



MERIDIAN BIOSCIENCE INC Rank 5 of 48





MEDICINAL PRODUCTS 2023



MERIDIAN BIOSCIENCE INC Rank 5 of 48

The relative strengths and weaknesses of MERIDIAN BIOSCIENCE INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MERIDIAN BIOSCIENCE INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 66% points. The greatest weakness of MERIDIAN BIOSCIENCE INC is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 125%, being 130% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	210,597
Assets, Non-Current	207,642
General and Administrative Expense	233,083
Goodwill	190,433
Liabilities, Current	58,529
Liabilities, Non-Current	37,085
Other Assets	-190,433
Other Compr. Net Income	-10,702
Other Expenses	33,067
Other Liabilities	-578
Other Net Income	-74
Other Revenues	333,018
Property, Plant and Equipment, Net	44,858
Research and Development	24,335

Output Variable	Value in 1000 USD
Liabilities	95,036
Assets	463,097
Expenses	290,485
Revenues	333,018
Stockholders Equity	368,061
Net Income	42,459
Comprehensive Net Income	37,108
Economic Capital Ratio	125%

